Current sodium channel inhibitors for local anesthesia and developing sodium channel inhibitors have some CNS and cardiovascular-related side effects due to their lack of selectivity. We hope that our selective voltage-gated sodium channel inhibitor will have good analgesic efficacy without CNS, cardiovascular, and muscular-related safety issues and might become one of best approaches to cure the peripheral neuropathic pain, including the infantile episodic limb pain syndrome for which there are no effective drugs.
ANP-390 is a selective Nav1.7 inhibtor, different from ANP-230. ANP-390 also has less CNS- related and CV-related side effects, which current analgesic drugs usually induce. In addition to it, it is expected that ANP-390 has efficacy for not only peripheral neuropathic pain but also peripheral itch.
When the peripheral sensory nerves are damaged, the expression level of Na+ channels in the damaged area and the dorsal root ganglion of the spinal cord is modulated, and the neuronal cells are overexcited to continuously transmit pain signals.ANP-230 is expected to reduce pain by suppressing its abnormal neuronal excitation.